The estimated Net Worth of Ralf Rosskamp is at least $901 mil dollars as of 26 December 2019. Ralf Rosskamp owns over 20,000 units of Dicerna Pharmaceuticals Inc stock worth over $900,616 and over the last 7 years Ralf sold DRNA stock worth over $0.
Ralf has made over 1 trades of the Dicerna Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Ralf exercised 20,000 units of DRNA stock worth $58,200 on 26 December 2019.
The largest trade Ralf's ever made was exercising 20,000 units of Dicerna Pharmaceuticals Inc stock on 26 December 2019 worth over $58,200. On average, Ralf trades about 4,000 units every 0 days since 2017. As of 26 December 2019 Ralf still owns at least 23,564 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Ralf Rosskamp stock trades at the bottom of the page.
Ralf's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 33 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo, ePeter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: